A prospective cohort study of Functional and Immunological outcomes after Laparoscopic and Robotic Total Meso-rectal Excision for rectal cancer

Portsmouth Hospitals NHS Trust0 个研究点目标入组 80 人开始时间: 2022年8月8日最近更新: 2022年8月22日

试验速览

暂无简介。

•1. Age 18 years or above.
•2. Diagnosed with rectal cancer, up to 15cm from the anal verge.
•3. Local MDT recommends rectal cancer surgery (i.e. (high) anterior resection, partial TME, complete TME)
•4. Patient assessed as fit for surgery (ASA I-III).
•5. Patient willing and able to give informed consent for participation in the study.
•6. Elective surgery.

•1. Patient planned for Abdominoperineal Excision of Rectum (APER) or Hartmann’s procedure
•2. Patients with confirmed or suspected metastatic disease.
•3. Pregnant or breastfeeding patients.
•4. Previous pelvic radiation for other cancers.
•5. Inflammatory bowel disease (IBD).
•6. Other known auto-immune disease which might influence the immune response (such as advanced liver disease, human immunodeficiency virus infection, Hepatitis B or C virus).
•7. Use of anti-inflammatory medication (i.e. corticosteroids, anti-inflammatory drugs, immune modulating drugs, chronic use of antibiotics (the use of NSAIDS and steroid asthma inhalers will not be considered an exclusion criteria).
•8. High pre-operative C-reactive protein (CRP) levels (>20).

发起方